An in vivo study using a transgenic mouse model characterized by a dominant-negative IGF-1R specifically targeted the skeletal muscle (KR-IGF-1R) demonstrated glucose intolerance at 8 weeks of age and overt diabetes at 12 weeks of age [74]. This evidence concerns the gene IGF1R and diabetes mellitus.